Please assess the completion status of the following clinical trial:

Trial Title: Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 19 years or older.~* The subjects who give written consent to participate in the study voluntarily and are able to comply with all study requirements.~* If female and capable of bearing children,subject has a negative urine pregnancy test result on screening and agrees to employ adequate birth control measures through the study period.~Exclusion Criteria:~* Subjects who are hypersensitive to any component of vaccine, i.e., eggs, chicken or chicken products.~* Subjects with immune deficiency disorder.~* History of Guillain-Barre syndrome.~* Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination.~* Subjects who experienced fever within 24 hours before vaccination or with the febrile disease(exceeding 38.0℃) on screening day or with any acute respiratory infection.~* Subjects who had received immunosuppressant or immune-modifying drug within 3 months before screening.~* Subjects who had received blood products or immunoglobulin within 3 months before screening.~* Subjects who had received influenza vaccination within 6 months prior to the screening.~* Subjects who had received other vaccination within a month before screening, or those who had another vaccination scheduled within a month after study vaccination.~* Subjects who had participated in other clinical trial within 4 weeks prior to study vaccination.~* Subjects who had done blood donation within a week prior to study vaccination or planned blood donation within 7 months after study vaccination.~* Subjects with clinically significant chronic disease or malignant cancer.~* Pregnant women, breast-feeding women.~* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- NBP607 (Type: EXPERIMENTAL): cell culture-derived trivalent inactivated subunit influenza vaccine
- Agrippal S1 (Type: ACTIVE_COMPARATOR): egg-derived trivalent inactivated subunit influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).